LANCY(SZ:002612)2023-10-30 16:00Financial Performance - The net profit attributable to the parent company reached CNY 193,900,575.79, a significant increase of 585.75% compared to the same period last year[11]. - The company reported a significant increase in the number of shares held by the top ten shareholders, with the largest shareholder holding 47.82% of the total shares[5]. - The company achieved a net profit of CNY 253,512,947.59, significantly higher than CNY 36,612,525.63 in the same period last year, marking a growth of 591.5%[45]. - The net profit attributable to shareholders was approximately $193.90 million, compared to $28.28 million in the same period last year, marking an increase of about 685%[48]. - Basic and diluted earnings per share were both $0.4382, up from $0.0639 in the previous year, reflecting a growth of over 585%[48]. - Total comprehensive income amounted to approximately $189.38 million, compared to $26.76 million in the prior year, indicating an increase of over 610%[48]. Revenue and Income - Total operating revenue of CNY 3,693,785,350.45 for the current period, an increase of 22.1% compared to CNY 3,026,252,507.86 in the previous period[45]. - Interest income surged by 264.55% to CNY 6,272,591.97, primarily due to an increase in interest revenue[11]. - Other income increased by 389.77% to CNY 15,884,682.30, mainly from higher government subsidies received[11]. - Investment income rose by 83.71% to CNY 52,386,769.44, attributed to increased earnings from associated companies and gains from the disposal of long-term equity investments[11]. - The company reported an increase in investment income to CNY 52,386,769.44, up from CNY 28,515,239.66, representing an increase of 83.8%[45]. Costs and Expenses - Total operating costs amounted to CNY 3,525,605,670.71, up 17.1% from CNY 3,009,994,089.94 in the previous period[45]. - Tax expenses increased significantly to CNY 35,242,446.89, reflecting a rise in income[11]. - The company reported a 55.30% increase in tax and surcharges, amounting to CNY 17,558,403.36, due to revenue growth[11]. - The company recorded a 169.69% increase in credit impairment losses, totaling CNY 3,786,754.30, due to an increase in accounts receivable[11]. - Research and development expenses decreased to CNY 68,415,334.09 from CNY 84,305,069.55, reflecting a reduction of 18.9%[45]. Assets and Liabilities - The company's total assets decreased by 2.97% to ¥7,479,447,744.17 from ¥7,110,249,238.41[23]. - Current liabilities totaled approximately $2.62 billion, a decrease from $2.75 billion in the previous period, reflecting a reduction of about 4.8%[53]. - Non-current liabilities decreased to approximately $1.13 billion from $1.42 billion, representing a decline of about 20%[53]. - Total liabilities amounted to approximately $3.76 billion, down from $4.17 billion, indicating a reduction of about 9.9%[53]. - Total equity attributable to shareholders increased to approximately $3.02 billion from $2.83 billion, reflecting a growth of about 6.7%[53]. Cash Flow - The company reported a net cash flow from operating activities of ¥84.15 million, reflecting an increase of 83.76%[23]. - The net cash flow from operating activities for the current period is ¥585,574,784.15, an increase of 83.7% compared to ¥318,663,720.54 in the previous period[57]. - Cash inflow from operating activities totaled ¥3,842,493,869.23, up from ¥3,319,641,339.91, representing a growth of 15.8%[57]. - Cash outflow from operating activities increased to ¥3,256,919,085.08 from ¥3,000,977,619.37, marking a rise of 8.5%[57]. - The net cash flow from investing activities was -¥354,125,105.05, worsening from -¥84,571,695.57 in the previous period[57]. Investments and Acquisitions - The company plans to acquire 75% of Wuhan Wuzhou and 70% of Wuhan Hancheng for a total cash consideration of CNY 28,088.00 million and CNY 10,123.00 million respectively[34]. - The company has established a new investment fund, Boheng No. 2, with a total fund size of CNY 81 million, contributing CNY 38 million as a limited partner[36]. - The company intends to issue A-shares to specific investors, raising up to CNY 166,778.82 million for new medical beauty hospital projects[38]. - The company has completed the consolidation of Wuhan Wuzhou and Wuhan Hancheng into its financial statements in Q3 2023[35]. Cash Management - Cash and cash equivalents decreased by 31.96% to ¥302,029,827.65 from ¥443,924,773.16 due to increased cash payments for external investments[21]. - The ending balance of cash and cash equivalents decreased to ¥293,458,827.65 from ¥473,698,843.94, a drop of 38.0%[60]. - Cash inflow from financing activities amounted to ¥1,222,017,230.55, compared to ¥1,011,243,000.00, reflecting an increase of 20.9%[60]. - The net cash flow from financing activities was -¥355,182,228.41, compared to -¥229,246,247.07 in the previous period, indicating a decline[60].